These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11136300)

  • 21. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
    Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
    Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
    Wang YH; Jones DR; Hall SD
    Drug Metab Dispos; 2004 Feb; 32(2):259-66. PubMed ID: 14744949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit.
    De Cicco M; Macor F; Robieux I; Zanette G; Fantin D; Fabiani F; Nicolosi G; Fracasso A; Toffoli G; Santantonio C; Lestuzzi C; Matovic M; Boiocchi M
    Crit Care Med; 1999 Feb; 27(2):332-9. PubMed ID: 10075058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil.
    Hashiguchi M; Ogata H; Maeda A; Hirashima Y; Ishii S; Mori Y; Amamoto T; Handa T; Otsuka N; Irie S; Urae A; Urae R; Kimura R
    J Clin Pharmacol; 1996 Nov; 36(11):1022-8. PubMed ID: 8973991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
    Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
    J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
    Piao YJ; Choi JS
    Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina.
    Gupta S; Modi NB; Sathyan G; Ho Pl PL; Aarons L
    Biopharm Drug Dispos; 2002 Jan; 23(1):17-31. PubMed ID: 11891670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.
    Kantola T; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Aug; 64(2):177-82. PubMed ID: 9728898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene.
    Mateus FH; Lepera JS; Marques MP; Boralli VB; Lanchote VL
    Can J Physiol Pharmacol; 2008 May; 86(5):232-9. PubMed ID: 18432283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats.
    Choi JS; Burm JP
    Arch Pharm Res; 2008 Sep; 31(9):1200-4. PubMed ID: 18806964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative pharmacokinetics of verapamil and norverapamil in normal and ulcerative colitis rats after oral administration of low and high dose verapamil by UPLC-MS/MS.
    Yao H; Wang C; Lu W; Li W; Jing W; Zhang J; Yang G; Zeng A
    Xenobiotica; 2020 Jun; 50(6):713-721. PubMed ID: 31633443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Yih BM; Atkinson L; Longstreth J
    J Clin Pharmacol; 1995 Nov; 35(11):1083-93. PubMed ID: 8626882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring of verapamil enantiomers concentration in overdose.
    Wilimowska J; Piekoszewski W; Krzyanowska-Kierepka E; Florek E
    Clin Toxicol (Phila); 2006; 44(2):169-71. PubMed ID: 16615674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers.
    Hunt BA; Bottorff MB; Herring VL; Self TH; Lalonde RL
    Clin Pharmacol Ther; 1990 May; 47(5):584-91. PubMed ID: 2344707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
    Chung JH; Choi DH; Choi JS
    Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereoselective first-pass metabolism of verapamil in the small intestine and liver in rats.
    Hanada K; Ikemi Y; Kukita K; Mihara K; Ogata H
    Drug Metab Dispos; 2008 Oct; 36(10):2037-42. PubMed ID: 18617604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats.
    Mateus FH; Lepera JS; Marques MP; Boralli VB; Lanchote VL
    Chirality; 2010 Jan; 22(1):29-34. PubMed ID: 19229957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-linear pharmacokinetics of high-dose intravenous verapamil.
    Toffoli G; Robieux I; Fantin D; Gigante M; Frustaci S; Nicolosi GL; De Cicco M; Boiocchi M
    Br J Clin Pharmacol; 1997 Sep; 44(3):255-60. PubMed ID: 9296319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous first-order and capacity-limited elimination kinetics after oral administration of verapamil.
    Gupta SK; Hwang S; Atkinson L; Longstreth J
    J Clin Pharmacol; 1996 Jan; 36(1):25-34. PubMed ID: 8932540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.